Skip to main content
Smart Investors Daily
AR

NASDAQ · ARCT

Arcturus Therapeutics Holdings Inc.

Healthcare · Biotechnology

$8.04

Down-$0.22 (-2.74%)

Updated Nov 19, 2026, 4:21 PM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
233.85M
P/E ratio
-3.35
Dividend yield
0.00%
52-week range
$5.50 – $17.96
Volume
637.89K
Avg. volume
553.54K

Price performance · ARCT

ARCT price history

1M range · 0 trading sessions · Daily adjusted prices

ARCT does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ARCT news

The latest Smart Investors Daily articles mentioning ARCT.

ARCT research

Overview

Company profile and research snapshot.

Company profile

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$54.00
Implied upside
—
Analysts
—
ARCT recent ratings
DateFirmRatingTarget
Oct 9, 2026Leerink PartnersOutperform—
Sep 24, 2026BTIGBuy—
Sep 24, 2026CitigroupBuy—
Jul 2, 2026Freedom BrokerBuy—
Mar 18, 2026B. Riley SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 16, 2026

Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration

SAN DIEGO, November 16, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced an expanded collaboration with Meiji Seika Pharma Co., Ltd. ("Meiji"), including a $50 million equity investment at an 80% premium. The expanded partnership includes a memorandum of understanding ("MOU") related to pandemic preparedness and response in Japan and an exclusive

Yahoo · Nov 6, 2026

What Arcturus Therapeutics (ARCT) Said on Its Q3 Earnings Call

Arcturus Therapeutics (NASDAQ:ARCT) expects to complete enrollment in a mid-stage cystic fibrosis study by the end of 2026 and begin dosing a next-generation treatment for a rare liver disorder in the first quarter of 2027, executives said on the company’s third-quarter earnings call. The company r

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.